Amarin (NASDAQ:AMRN) Earns Overweight Rating from Cantor Fitzgerald

Amarin (NASDAQ:AMRN - Get Free Report)'s stock had its "overweight" rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports.

Separately, StockNews.com upgraded shares of Amarin from a "hold" rating to a "buy" rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Amarin has an average rating of "Hold" and a consensus target price of $1.08.

Amarin Stock Down 3.7 %

Shares of AMRN traded down $0.03 during midday trading on Tuesday, hitting $0.73. The company had a trading volume of 1,163,746 shares, compared to its average volume of 1,873,523. The company's 50 day moving average price is $0.86 and its 200 day moving average price is $0.96. The stock has a market cap of $299.83 million, a price-to-earnings ratio of -6.08 and a beta of 1.99. Amarin has a 52 week low of $0.63 and a 52 week high of $1.49.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. The business had revenue of $56.52 million during the quarter, compared to the consensus estimate of $51.34 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. Equities analysts anticipate that Amarin will post -0.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 34,725 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Amarin by 100.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 23,313 shares during the period. SVB Wealth LLC lifted its stake in shares of Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company's stock worth $52,000 after acquiring an additional 30,000 shares during the period. LCM Capital Management Inc lifted its stake in shares of Amarin by 5.1% in the 4th quarter. LCM Capital Management Inc now owns 740,159 shares of the biopharmaceutical company's stock worth $644,000 after acquiring an additional 36,000 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Amarin by 705.2% in the 4th quarter. BNP Paribas Financial Markets now owns 455,177 shares of the biopharmaceutical company's stock worth $396,000 after acquiring an additional 398,648 shares during the period. Institutional investors own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.